TICKERNERD
Menu
GHRSGHRSHealthcare · Biotechnology

GHRS Stock Forecast: GH Research Plc Price Predictions for 2026-2027

Last close, 30 Oct 2026
$21
−2.98% on the day

The 10 Wall Street analysts covering GH Research Plc hold a median 12-month price target of $40 — +91.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$1.4B
Ticker Nerd rank
64/ 100
Median analyst target
$40
Analysts covering
10
Revenue$0.0
Operating income−$19.4M
Net income−$15.1M
Free cash flow−$15.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+15.4%
1M
−11.2%
YTD
+64.3%
1Y
+66.3%
From 52W high
−31.9%
From 52W low
+67.1%
$12
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GHRS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GH Research Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
64/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Value
75
Volatility
69
Quality
63
Revisions
62
Accruals
55
Issuance
43
Size
39
Growth
29

Momentum (83): The shares have been drifting up relative to others.

Growth (29): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GHRS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GHRS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Jan 26Apr 26Jul 26Oct 26GHRSHigh $65Median $40Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $38Median $40High $65

The green dot is the last close — the median target sits +91.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$35 → $40
7 Aug 2026GuggenheimMaintainsBuy$34 → $40
6 Aug 2026NeedhamMaintainsBuy$32 → $39
27 July 2026Wells FargoInitiatesOverweight—
27 July 2026Wells FargoInitiatesOverweight$44
19 May 2026HC Wainwright & Co.MaintainsBuy—
19 May 2026HC Wainwright & Co.MaintainsBuy$70 → $65
15 May 2026Cantor FitzgeraldMaintainsOverweight—
15 May 2026Cantor FitzgeraldMaintainsOverweight$25 → $35
15 May 2026CitizensMaintainsMarket Outperform$42 → $39
15 May 2026CitizensMaintainsMarket Outperform—
6 Mar 2026CitizensMaintainsMarket Outperform—
6 Mar 2026NeedhamMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026RBC CapitalMaintainsOutperform—
6 Jan 2026Canaccord GenuityMaintainsBuy—
6 Jan 2026NeedhamMaintainsBuy—
5 Jan 2026NeedhamReiteratesBuy—
10 Nov 2025HC Wainwright & Co.MaintainsBuy—
13 Oct 2025NeedhamInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GHRS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GHRS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, GH Research Plc returned +66.3% against +12.4% for the S&P 500, dividends included.

GHRS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26GHRSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GHRS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
8
Analysts cutting
0
Fundamentals

GH Research Plc (GHRS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−26.4×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
4.0×

Cheaper than 23% of US stocks

EV / EBITDA
−15.0×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−18.8%

Higher than 32% of US stocks

Return on assets
−13.0%

Higher than 24% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GH Research Plc (GHRS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GH Research Plc has a market value of $1.4B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$62.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$51.8M.

  • Shares outstanding: 68.6M.

  • Trailing P/E: −26.4×; forward P/E: −11.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • GH Research Plc employs 73 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

GHRS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GHRSGH Research Plc$1.4B64
ANABAnaptysBio, Inc.$1.4B94
TYRATyra Biosciences, Inc.$1.4B39
KRSAKorsana Biosciences, Inc.$1.4B37
LYCALycia Therapeutics, Inc.$1.5B0
OCULOcular Therapeutix, Inc.$1.5B29
TSHATaysha Gene Therapies, Inc.$1.3B41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GH Research Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GHRS news & analysis

GH Research Remains Undervalued Ahead Of Pivotal Phase III Program

Seeking Alpha · 23 Oct 2026positive

A Seeking Alpha article argues that GH Research is undervalued, citing unmet need in treatment-resistant depression, promising early GH001 data, and the company’s cash position. It notes that Phase III results and FDA approval are still needed, and that further dilution may occur before profitability.

Why it matters — GHRS watchers may weigh the article’s favorable view of GH001’s potential against the remaining clinical, regulatory, and financing risks.

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

Seeking Alpha · 20 Sept 2026positive

Seeking Alpha initiated coverage on GH Research PLC with a "Buy" rating, citing renewed momentum in its GH001 program for treatment-resistant depression. The company has resolved the FDA clinical hold on its GH001 IND, positioning it for a pivotal phase 3 trial expected to start in 2026. GH001 offers competitive advantages, including the shortest-acting psychedelic (an 11-minute psychoactive phase) and fewer treatment visits than SPRAVATO and BPL-003.

Why it matters — A GHRS watcher would care because resolution of the FDA clinical hold and progress toward a pivotal phase 3 trial represent meaningful advancement of the company's lead GH001 program for treatment-resistant depression.

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026positive

GH Research reported second quarter 2026 financial results and a business update. Highlights include FDA alignment on CMC and device plans for the Phase 3 program of GH001 in treatment-resistant depression, completion of two Phase 1 trials (GH001-HV-106 and GH001-HV-109), publication of Phase 2a postpartum depression results in The Journal of Clinical Psychiatry, a strengthened US and EU mebufotenin patent estate, and cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026.

Why it matters — A GHRS watcher would note progress toward the Phase 3 program, recent trial completions, publication of Phase 2a data, and a substantial cash position that supports ongoing development.

FAQ

Frequently asked questions about GHRS stock

What is the GHRS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering GH Research Plc have a median 12-month price target of $40, with estimates ranging from $38 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GHRS stock a buy right now?

Of the 10 analysts covering GH Research Plc, 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GH Research Plc 64 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GHRS?

As at 31 Oct 2026, GH Research Plc ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will GHRS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +91.8% from the last close, and Ticker Nerd's factor model ranks GH Research Plc 64 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GHRS stock forecast for 2030?

No analyst covering GH Research Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $65 over the next 12 months.

How has GHRS stock performed over the past year?

GH Research Plc returned +66.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GH Research Plc do?

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development.

What is the latest news on GHRS?

The most recent item we track (Seeking Alpha, 23 Oct 2026): "GH Research Remains Undervalued Ahead Of Pivotal Phase III Program". A Seeking Alpha article argues that GH Research is undervalued, citing unmet need in treatment-resistant depression, promising early GH001 data, and the company’s cash position. It notes that Phase III results and FDA approval are still needed, and that further dilution may occur before profitability.

Company

About GH Research Plc.

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.

CEO Dr. Theis Terwey M.D. · 73 employees · Ireland · https://www.ghres.com